

Supplemental Table 1: Clinicopathologic Characteristics of Patients Undergoing Local Treatment for PCa

Category	N=1734 (%)	Metformin Use		P-Value
		No N=1,368 (%)	Yes N=366 (%)	
Age (years)		(%)		
<65	969 (56)	771 (56)	198 (54)	0.66
65-74	600 (35)	466 (34)	134 (37)	
75+	165 (10)	131 (10)	34 (9)	
Race				0.015
White	1,467 (85)	1,174 (86)	293 (80)	
Black	152 (9)	107 (8)	45 (12)	
Other	115 (7)	87 (6)	28 (8)	
Body Mass Index (kg/m²)				<0.001
<24.9	297 (17)	262 (19)	35 (10)	
25.0-29.9	710 (41)	611 (45)	99 (27)	
30+	723 (42)	492 (36)	231 (63)	
Charlson Score				<0.001
None	755 (44)	707 (53)	48 (13)	
1	504 (30)	381 (28)	123 (34)	
2-3	321 (19)	198 (15)	123 (34)	
4+	126 (7)	59 (4)	67 (19)	
Baseline PSA (ng/mL)				0.009
<4	146 (8)	105 (8)	41 (11)	
4-9.9	1,093 (63)	850 (62)	243 (66)	
10-19.9	387 (22)	325 (24)	62 (17)	
20+	108 (6)	88 (6)	20 (6)	
Gleason Score				0.014
6	667 (39)	550 (40)	117 (32)	
7	758 (44)	578 (42)	180 (49)	
8-10	302 (18)	235 (17)	67 (18)	
Clinical Stage				0.238
T1-T2a	1,405 (25)	1,103 (81)	302 (83)	
T2b-T2c	299 (17)	244 (18)	55 (15)	
T3+	30 (2)	21 (2)	9 (2)	
D'Amico Risk Category				0.782
Low	433 (25)	346 (25)	87 (24)	
Intermediate	914 (53)	720 (53)	194 (53)	
High	385 (22)	300 (22)	85 (23)	

PCa: prostate cancer; kg/m²: kilograms per meters squared; PSA: prostate specific antigen; ng/mL: nanograms per milliliter.

Supplemental Table 2: Demographics of Men Undergoing Prostate Needle Biopsy Relative to Metformin Usage

	Metformin	No Metformin
<i>N</i>	48	42
<i>Age (years)</i>		
< 60	6 (12.5)	5 (11.9)
60 – 69	31 (64.6)	29 (69)
• •	11 (22.9)	8 (19)
<i>Race</i>		
Caucasian	39 (81.3)	35 (83.3)
African American	7 (14.6)	5 (11.9)
Other	2 (4.2)	2 (4.8)
<i>Body Mass Index (kg/m²)</i>		
20 – 24	7 (14.6)	6 (14.3)
25 – 29	13 (27.1)	11 (26.2)
• •	28 (58.3)	25 (59.5)
<i>PSA (ng/mL)</i>		
< 4.0	8 (16.7)	8 (19)
4 – 9	33 (68.8)	26 (61.9)
• •	7 (14.6)	8 (19)
<i>Family History of PCa</i>		
No	39 (81.3)	37 (88.1)
Yes	9 (18.8)	5 (11.9)
<i>PCa on biopsy</i>		
No	27 (56.3)	23 (54.8)
Yes	21 (43.8)	19 (45.2)
<i>Fasting glucose</i>		
• • • • •	18 (37.5)	39 (92.9)
> 125mg/dl	30 (62.5)	3 (7.1)

BMI: body mass index; PCa: prostate cancer; kg/m²: kilograms per meters squared; ng/mL: nanograms per milliliter; mg/dL: milligrams per deciliter.